Tenecteplase in Patients With COVID-19

COVID-19 Clinical Trial

Official title:

Tenecteplase With Concomitant Anticoagulation for Severe Acute Respiratory Failure in Patients With COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04505592
• Other study ID #: GCO 20-1764
• Status: Completed
• Phase: Phase 2
• Start date: September 25, 2020
• Est. completion date: March 10, 2022

Study information

• Verified date: April 2023
• Source: Icahn School of Medicine at Mount Sinai
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a placebo-controlled, double blind, randomized, Phase II dose escalation study intended to evaluate the potential safety and efficacy of tenecteplase for the treatment of COVID-19 associated respiratory failure. The hypothesis is that administration of the drug, in conjunction with heparin anticoagulation, will improve patients' clinical outcomes.

Description:

Patients with COVID-19 who suffer from acute hypoxemic respiratory failure have a poor prognosis. COVID-19 has been associated with a hyperinflammatory and hypercoagulable state, leading to a range of thromboembolic complications from pulmonary embolism to ischemic stroke. Furthermore, emerging data suggest that the associated acute respiratory failure is, at least in part, due to pulmonary vascular disease caused by micro- and/or macro-emboli, creating pulmonary vascular shunting and dead-space ventilation. In this placebo-controlled, double blind, randomized, Phase II dose escalation study, we plan to evaluate the clinical efficacy and safety of low-dose IV bolus tenecteplase together with anticoagulation compared with control patients on therapeutic anticoagulation alone in hospitalized adults diagnosed with COVID-19 respiratory failure with elevated D-dimer. We believe these patients can be successfully treated without significantly increasing the risk of major bleeding while improving recovery rates, shorten hospitalization time, and perhaps ultimately prove to improve survival.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: March 10, 2022
• Est. primary completion date: March 10, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria

• Patient/legally authorized representative has completed the Informed Consent Form

• Age =18 years

• Ability to comply with the study protocol, in the investigator's judgment

• Respiratory failure secondary to COVID-19 requiring mechanical ventilation for no greater than 24 hours, or high-flow nasal cannula (HFNC),non-rebreather (NRB) mask or non-invasive positive pressure ventilation (NIPPV) for no greater than 48 hours

• Confirmed infection with SARS-CoV-2 virus (PCR positive within 14 days)

• Elevated D-dimer (>6 times upper limit of normal within past 72 hours)

• For patient who are intubated >12 hours prior to randomization or with any evidence of neurologic deficit a head CT within 12 hours demonstrating no evidence of acute or subacute infarct or hemorrhage

Exclusion Criteria

• Current participation in another investigational drug study within the prior 7 days

• Known hypersensitivity or allergy to any ingredients of tenecteplase

• Active internal bleeding

• Known bleeding diathesis

• Use of one of the new oral anticoagulants within the last 48 hours (dabigatran, rivaroxaban, apixaban, edoxaban)

• Treatment with a thrombolytic within the last 3 months prior to randomization (exception for the use of Cathflo alteplase for occlusions of central venous catheters)

• Baseline platelet count <80,000/L (results must be available prior to treatment)

• Baseline blood glucose >400 mg/dL (22.20 mmol/L)

• Baseline blood glucose <50 mg/dL needs to be normalized prior to randomization

• Intracranial or intraspinal surgery or trauma within 2 months

• Other, non-COVID-19 related, serious, advanced, or terminal illness (investigator judgment) or life expectancy is less than 6 months

• History of acute ischemic stroke in the last 90 days

• History of intracranial bleeding, including hemorrhagic stroke

• Presumed septic embolus; suspicion of bacterial endocarditis

• Mechanical ventilation > 24 hours, HFNC, NRB, NIPPV, or any combination, for greater than 48 hours

• Mechanical ventilation, HFNC, NRB, or NIPVV (for reasons other than obstructive sleep apnea) within the prior 30 days (excluding 48 hours prior to randomization)

• Moribund status suggesting imminent vascular collapse and inability to survive > 72 hours (investigator determination)

• Uncontrolled hypertension defined as systolic BP > 180 mm Hg and/or diastolic BP > 110 mm Hgb

• Age > 75 years

• History of traumatic brain injury within 2 months

• Recent head trauma with fracture or brain injury

• History of Heparin Induced Thrombocytopenia (HIT) and/or other hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency

• INR > 2 or recent oral anticoagulant therapy with INR >1.7

• Pregnancy or lactation within the prior 30 days; women of childbearing age (<55 years old) should have documentation of a negative pregnancy test

• Chronic liver disease defined as > Childs-Pugh Class B

• Atrial fibrillation, mitral stenosis, or known left heart thrombosis

• Any other condition that, in the opinion of the investigator, precludes administration of tenecteplase or poses a significant hazard to the patient receives tenecteplase

Related Conditions & MeSH terms

• ARDS
• COVID-19
• Respiratory Failure
• Respiratory Insufficiency

Intervention

Drug:
• Tenecteplase
First 20 patients randomized to treatment arm will receive 0.25 mg/kg of tenecteplase. Next 20 patients randomized to treatment arm will receive 0.50 mg/kg of tenecteplase. Both will receive concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
• Placebo
Patients will receive placebo with concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.

Locations

Country	Name	City	State
United States	Mount Sinai Hospital	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Hooman Poor	Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Free of Respiratory Failure	The number of patients free of respiratory failure defined as not requiring high flow nasal cannula, non-rebreather, noninvasive positive pressure ventilation, or mechanical ventilation at 28 days	28 Days
Primary	Number of Participants With Occurrences of Bleeding	Safety as assessed by number of participants with occurrences of intracranial bleeding or major bleeding	28 days
Secondary	Number of Participants With In-hospital Deaths at 14 Days	Number of patients who expired in the hospital within the first 14 days of their participation in the study	14 days
Secondary	Number of Participants With Death at 28 Days	Number of participants who expired by 28 days/end of study	28 days
Secondary	Number of Ventilator-free Days	Number of ventilator-free days in 28 days period	28 days
Secondary	Number of Respiratory Failure-free Days	Respiratory failure-free defined as not requiring high flow nasal cannula, non-rebreather, noninvasive positive pressure ventilation, or mechanical ventilation. Number of respiratory failure-free days in 28 days period.	28 days
Secondary	Number of Vasopressor-free Days	Number of vasopressor-free days over 28 days period	28 days
Secondary	Number of Vasopressor Doses at 24 Hours		24 hours and 72 hours
Secondary	P/F Ratio	The P/F ratio equals the arterial pO2 ("P") from the ABG divided by the FIO2 ("F") - the fraction (percent) of inspired oxygen that the patient is receiving expressed as a decimal (40% oxygen = FIO2 of 0.40).; Ratio of arterial pO2 over fraction of inspired oxygen that the person is receiving.; Normal P/F Ratio is = 400.; 300 to 200 is considered mild ARDS; 200 to 100 is considered moderate ARDS; Anything below 100 is considered severe ARDS.	24 hours and 72 hours
Secondary	Number of ICU-free Days	Number of days the patient spent outside the ICU	28 days
Secondary	Hospital Length of Stay	Length of time the patient spent in the hospital, including ICU	up to 29 days
Secondary	Number of Participants With New-onset Renal Failure	Number of patients who experienced renal failure during the course of the study	28 days
Secondary	Number of Participants With Need for Renal Replacement Therapy	Number of patients who underwent renal replacement treatment for their renal failure	28 days